Nuvalent (NUVL) Competitors $74.11 +1.95 (+2.70%) Closing price 08/8/2025 04:00 PM EasternExtended Trading$74.88 +0.77 (+1.04%) As of 08/8/2025 04:37 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock NUVL vs. INSM, SMMT, TEVA, GMAB, RDY, QGEN, MRNA, ASND, VTRS, and BBIOShould you be buying Nuvalent stock or one of its competitors? The main competitors of Nuvalent include Insmed (INSM), Summit Therapeutics (SMMT), Teva Pharmaceutical Industries (TEVA), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Qiagen (QGEN), Moderna (MRNA), Ascendis Pharma A/S (ASND), Viatris (VTRS), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical products" industry. Nuvalent vs. Its Competitors Insmed Summit Therapeutics Teva Pharmaceutical Industries Genmab A/S Dr. Reddy's Laboratories Qiagen Moderna Ascendis Pharma A/S Viatris BridgeBio Pharma Insmed (NASDAQ:INSM) and Nuvalent (NASDAQ:NUVL) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their risk, institutional ownership, earnings, dividends, media sentiment, valuation, profitability and analyst recommendations. Do insiders and institutionals believe in INSM or NUVL? 97.3% of Nuvalent shares are held by institutional investors. 3.0% of Insmed shares are held by insiders. Comparatively, 10.2% of Nuvalent shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth. Does the media refer more to INSM or NUVL? In the previous week, Insmed had 3 more articles in the media than Nuvalent. MarketBeat recorded 13 mentions for Insmed and 10 mentions for Nuvalent. Insmed's average media sentiment score of 0.57 beat Nuvalent's score of 0.45 indicating that Insmed is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Insmed 4 Very Positive mention(s) 0 Positive mention(s) 5 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Positive Nuvalent 4 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Do analysts prefer INSM or NUVL? Insmed presently has a consensus target price of $112.71, indicating a potential upside of 2.89%. Nuvalent has a consensus target price of $119.60, indicating a potential upside of 61.38%. Given Nuvalent's stronger consensus rating and higher probable upside, analysts clearly believe Nuvalent is more favorable than Insmed.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Insmed 0 Sell rating(s) 0 Hold rating(s) 16 Buy rating(s) 0 Strong Buy rating(s) 3.00Nuvalent 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 1 Strong Buy rating(s) 3.09 Is INSM or NUVL more profitable? Nuvalent has a net margin of 0.00% compared to Insmed's net margin of -259.82%. Nuvalent's return on equity of -31.60% beat Insmed's return on equity.Company Net Margins Return on Equity Return on Assets Insmed-259.82% -357.51% -52.76% Nuvalent N/A -31.60%-29.45% Which has stronger earnings & valuation, INSM or NUVL? Nuvalent has lower revenue, but higher earnings than Insmed. Insmed is trading at a lower price-to-earnings ratio than Nuvalent, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioInsmed$363.71M57.14-$913.77M-$5.95-18.41NuvalentN/AN/A-$260.76M-$4.39-16.88 Which has more risk & volatility, INSM or NUVL? Insmed has a beta of 0.95, suggesting that its share price is 5% less volatile than the S&P 500. Comparatively, Nuvalent has a beta of 1.3, suggesting that its share price is 30% more volatile than the S&P 500. SummaryNuvalent beats Insmed on 12 of the 16 factors compared between the two stocks. Get Nuvalent News Delivered to You Automatically Sign up to receive the latest news and ratings for NUVL and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding NUVL and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart NUVL vs. The Competition Export to ExcelMetricNuvalentMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$5.32B$2.99B$5.51B$9.72BDividend YieldN/A2.45%4.60%4.12%P/E Ratio-15.1217.2130.0324.76Price / SalesN/A319.03452.4198.43Price / CashN/A41.7736.7758.47Price / Book4.947.318.185.59Net Income-$260.76M-$54.43M$3.26B$265.99M7 Day Performance-4.69%0.01%6.13%5.07%1 Month Performance-9.70%0.63%0.07%0.61%1 Year Performance5.89%8.41%36.31%22.83% Nuvalent Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)NUVLNuvalent3.1285 of 5 stars$74.11+2.7%$119.60+61.4%+5.9%$5.32BN/A-15.1240News CoveragePositive NewsEarnings ReportUpcoming EarningsInsider TradeAnalyst RevisionINSMInsmed3.7647 of 5 stars$111.24+2.3%$109.20-1.8%+48.1%$20.62B$363.71M-18.701,271Trending NewsEarnings ReportAnalyst ForecastAnalyst RevisionSMMTSummit Therapeutics1.9967 of 5 stars$29.32+8.3%$34.67+18.2%+165.9%$20.10B$700K-86.23110Upcoming EarningsOptions VolumeTEVATeva Pharmaceutical Industries2.9393 of 5 stars$15.70+2.1%$24.71+57.4%-6.2%$17.64B$16.54B-98.1336,830Insider TradeGMABGenmab A/S3.7036 of 5 stars$21.98+0.9%$37.80+72.0%-18.9%$13.97B$3.12B12.492,682Trending NewsEarnings ReportShort Interest ↑Analyst RevisionRDYDr. Reddy's Laboratories2.5458 of 5 stars$13.80-1.0%$16.95+22.9%-17.6%$11.64B$334.26B20.9027,811News CoveragePositive NewsQGENQiagen3.5567 of 5 stars$50.27+0.7%$49.40-1.7%+8.7%$11.10B$1.98B126.045,765News CoverageEarnings ReportAnalyst ForecastAnalyst RevisionMRNAModerna4.3321 of 5 stars$27.64+0.1%$45.61+65.0%-69.2%$10.68B$3.24B-3.675,800Earnings ReportAnalyst RevisionGap DownASNDAscendis Pharma A/S3.4225 of 5 stars$184.15+5.5%$223.67+21.5%+50.8%$10.67B$393.54M-29.321,017Trending NewsEarnings ReportAnalyst ForecastGap UpVTRSViatris1.7928 of 5 stars$8.94+1.5%$10.40+16.3%-17.7%$10.34B$14.74B-2.8232,000Trending NewsEarnings ReportDividend AnnouncementAnalyst UpgradeShort Interest ↑BBIOBridgeBio Pharma4.7302 of 5 stars$47.75+0.8%$61.18+28.1%+90.7%$8.99B$221.90M-13.53400Trending NewsEarnings ReportAnalyst ForecastInsider TradeOptions VolumeAnalyst Revision Related Companies and Tools Related Companies INSM Competitors SMMT Competitors TEVA Competitors GMAB Competitors RDY Competitors QGEN Competitors MRNA Competitors ASND Competitors VTRS Competitors BBIO Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:NUVL) was last updated on 8/10/2025 by MarketBeat.com Staff From Our Partners[No Brainer Gold Play]: “Show me a better investment.”A Historic Gold Announcement Is About to Rock Wall Street? For months, sharp-eyed analysts have watched the...Golden Portfolio | SponsoredGENIUS Act: Cancel Your Money?A new law called the GENIUS Act could quietly trigger the most radical shift in American finance in decades. B...Priority Gold | SponsoredTrump’s national nightmare is herePorter Stansberry and Jeff Brown say a new U.S. national emergency is already underway — and it could trigger ...Porter & Company | SponsoredNational 'Stock Market Reset' Coming September 30 (New WH Order)Crash Coming Sept 30? Analysts Warn of New Crisis A new problem on the U.S. power grid is putting millions ...Altimetry | Sponsored"Death Spiral" Threatening Your SavingsThe "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCritical AI announcement set to ignite AI 2.0 I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Nuvalent, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Nuvalent With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NUVL Stock Alerts